CLINICAL TRIALS PROFILE FOR TAMSULOSIN HYDROCHLORIDE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for TAMSULOSIN HYDROCHLORIDE
Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|---|
OTC | NCT01726270 ↗ | An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms | Completed | Boehringer Ingelheim | Phase 2 | 2012-11-01 | Multicenter trial conducted in Pharmacy retail centers |
OTC | NCT02573311 ↗ | Actual Use Study of Tamsulosin in Men | Completed | Boehringer Ingelheim | Phase 3 | 2015-09-23 | An actual use study to assess how men who respond to advertisements about urinary symptoms use tamsulosin in a simulated Over the Counter (OTC) setting including following "stop use and ask a doctor if" and "ask a doctor before use" statements and if they take the medication according to the label instructions, also assess any reported adverse events during simulated OTC use. |
>Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for TAMSULOSIN HYDROCHLORIDE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00090103 ↗ | Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment | Completed | GlaxoSmithKline | Phase 3 | 2003-11-01 | This study will investigate the efficacy and safety of treatment with dutasteride and tamsulosin, administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic Benign Prostatic Hyperplasia (BPH). Study visits are every 3 months for up to 4 years (18 clinic visits). Transrectal ultrasound (TRUS) is done annually. |
NCT00147654 ↗ | Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction | Completed | Pfizer | Phase 4 | 2004-11-01 | The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge incontinence (UUI), with or without bladder outlet obstruction (BOO). |
NCT00147654 ↗ | Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | 2004-11-01 | The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge incontinence (UUI), with or without bladder outlet obstruction (BOO). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TAMSULOSIN HYDROCHLORIDE
Condition Name
Clinical Trial Locations for TAMSULOSIN HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for TAMSULOSIN HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for TAMSULOSIN HYDROCHLORIDE
Sponsor Name